EQUITY-BASED COMPENSATION (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jul. 20, 2023	May 02, 2023
Common stock, shares issued	47,422,304	43,448,317	2,500,000	913,234
Common stock, shares authorized	600,000,000	600,000,000
Stock Compensation Plans [Member]
Common stock, shares issued	153,195
Common stock, shares authorized	634,000
Stock Bonus Plans [Member]
Common stock, shares issued	512,972
Common stock, shares authorized	1,283,760
Non-Qualified Stock Options Plans [Member]
Common stock, shares authorized	15,787,200
Issuance of common stock options authorized shares	2,000,000	2,000,000
Performance based stock options shares granted	1,958,500	250,000
Stock price	$ 1.36	$ 10.48
Stock options vest description		The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon the Company’s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia
Incentive Stock Option Plans [Member]
Common stock, shares authorized	138,400
Incentive Stock Bonus Plan [Member]
Forfeited	(4,000)
Common stock, shares authorized	610,500
Grant date fair value remaining outstanding	$ 8,600,000
Vested shares	463,250
Unrecognized compensation expense	$ 22,000	$ 45,000,000
Restricted Stock Awards [Member]
Total compensation cost	$ 300,000
Weighted-average period	11 months 8 days
Forfeited	(4,000)	0
Non Vested Options [Member]
Total compensation cost	$ 6,900,000
Weighted-average period	1 year 9 months 10 days